Abstract
Objective: Bioactive peptides (BP) have been widely pursued for the management of hypertension showing an angiotensin I converting enzyme (ACE) inhibitory capacity. They have been widely pursued for the management of hypertension and are believed to exert beneficial physiological effects on the endothelium. We aimed to test ACE inhibitory capacity of a protein hydrolysate containing characterized BP from Spanish dry-cured ham and four purified BP (KPVAAP, KAAAATP, KPGRP, AAATP). Secondly, the current study evaluates beneficial changes in protein expression changes and antioxidant activity over the endothelium. Design and method: ACE inhibitory activity of BP was evaluated using an enzymatic extract of transiently transfected EA.hy 926 endothelial cells. Potential mechanisms of action of BP over endothelial function were quantified by RT-PCR after treatment with TNF-α 100 ng/μl or H2O2 300 μM w/o BP. Results: Significant ACE inhibition was observed at different concentrations of cured ham hydrolysate and purified BP in a dose-response manner. The following IC 50 were found for each BP: Cured ham hydrolysate 410,34 ± 55,79 μg/ml, KPVAAP 108,79 ± 45,76 μM, KPGRP 485,50 ± 43,47 μM, AAATP 1317,32 ± 161,65 μM and KAAAATP 1267,54 ± 43,7516 μM. Cured ham hydrolysate at 50 μg/ml promoted antioxidant activity through catalase, superoxide dismutase and eNOS mRNA higher expression in the presence of H2O2 (p = 0.04, p = 0.04 and p = 0.01, respectively). It also prevented an adhesive marker expression such as ICAM-1 in the presence of TNF-α (p < 0.001). Moreover, purified AAATP (300 μM) also prevented the TNFα-increased ICAM-1 mRNA expression (p = 0.008). KPVAAP and AAATP reverted the TNF-α decreased eNOS mRNA expression (p = 0.02 and p = 0.04, respectively). Conclusions: Those results suggest protective effects of biopeptides against inflammation and oxidant agents as well as antihypertensive activity. Bioactive peptides from Spanish dry cured-ham could then display benefits in the cardiovascular system, with potential clinical relevance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.